KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) EBT (2016 - 2025)

Regeneron Pharmaceuticals has reported EBT over the past 17 years, most recently at $1.0 billion for Q4 2025.

  • Quarterly results put EBT at $1.0 billion for Q4 2025, up 8.93% from a year ago — trailing twelve months through Dec 2025 was $5.2 billion (up 9.43% YoY), and the annual figure for FY2025 was $5.2 billion, up 9.43%.
  • EBT for Q4 2025 was $1.0 billion at Regeneron Pharmaceuticals, down from $1.8 billion in the prior quarter.
  • Over the last five years, EBT for REGN hit a ceiling of $3.8 billion in Q2 2021 and a floor of $700.7 million in Q1 2024.
  • Median EBT over the past 5 years was $1.2 billion (2021), compared with a mean of $1.4 billion.
  • Biggest five-year swings in EBT: skyrocketed 308.4% in 2021 and later crashed 74.33% in 2022.
  • Regeneron Pharmaceuticals' EBT stood at $2.5 billion in 2021, then crashed by 47.08% to $1.3 billion in 2022, then dropped by 13.37% to $1.1 billion in 2023, then dropped by 16.51% to $958.1 million in 2024, then increased by 8.93% to $1.0 billion in 2025.
  • The last three reported values for EBT were $1.0 billion (Q4 2025), $1.8 billion (Q3 2025), and $1.5 billion (Q2 2025) per Business Quant data.